November 14, 2017 03:28 PM EST

Mirati bails on lead drug, shifts focus to I/O program

Brittany Meiling

The stock is sinking for San Diego biotech Mirati Therapeutics $MRTX following news that the company is siphoning resources from its lead drug to fund …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Mirati bails on lead drug, shifts focus to I/O program

Brittany Meiling

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Jazz wins approval for bispecific in biliary tract cancer

Amgen names Stanford geneticist and biotech founder to CSO post

Are programs with compounded GLP-1s safe for your population?

Mi­rati bails on lead drug, shifts fo­cus to I/O pro­gram

Brittany Meiling

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Mirati bails on lead drug, shifts focus to I/O program

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Jazz wins approval for bispecific in biliary tract cancer

Amgen names Stanford geneticist and biotech founder to CSO post

Are programs with compounded GLP-1s safe for your population?